Terapia Biológica y Moduladores del Sistema Inmunológico en el tratamiento de las Enfermedades Inflamatorias Intestinales
DOI:
https://doi.org/10.55204/scc.v2i2.e32Palabras clave:
enfermedades inflamatorias del intestino, enfermedad de Crohn, colitis ulcerosa, tratamiento biológico, agentes inmunomoduladoresResumen
Introducción: las enfermedades inflamatorias intestinales (EII) son trastornos crónicos del tracto gastrointestinal sin cura definitiva. La incidencia y prevalencia varían según la enfermedad y ubicación geográfica.
Objetivo: describir la terapia biológica y moduladores del sistema inmunológico en el tratamiento de las enfermedades inflamatorias intestinales.
Desarrollo: en la enfermedad de Crohn, la efectividad de los tratamientos varía, destacando Infliximab, Ustekinumab y Adalimumab en diferentes aspectos. Vedolizumab destaca en colitis ulcerosa. Los anti-TNF muestran cicatrización de mucosa efectiva. Vedolizumab es prometedor en respuesta, remisión. Metotrexato tiene efectos mixtos. En el manejo de la EII, los biológicos mejoran la calidad de vida, pero tienen costos más altos y diferentes relaciones costo-efectividad. También hay diferencias en riesgos de infecciones graves y linfoma según los tratamientos utilizados.
Conclusiones: Los estudios recientes proporcionan una visión completa de las terapias biológicas y los inmunomoduladores en el tratamiento de la EC y CU. Los resultados destacan la eficacia de diferentes opciones terapéuticas, resaltando la importancia de adaptar el tratamiento a las necesidades individuales de los pacientes y la presentación clínica de la enfermedad.
Descargas
Citas
Seyed N, Madgwick M, Sudhakar P. Big data in IBD: Big progress for clinical practice. Gut. 2020;69(8):1520–32.
Magro F, Gionchetti P, Eliakim R. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis. 2017;11(6):649–70.
Agrawal M, Spencer E, Colombel J. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User’s Guide for Adult and Pediatric Gastroenterologists. Gastroenterology. 2021;161(1):47–65.
Piovani D, Danese S, Peyrin L, Bonovas S. Inflammatory bowel disease: estimates from the global burden of disease 2017 study. Aliment Pharmacol Ther. 2020;51(2):261–70.
Guan Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J Immunol Res. 2019;2019(2):12–9.
Ng S, Shi H, Hamidi N. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(104):2769–78.
Khalili H. The Changing Epidemiology of Inflammatory Bowel Disease: What Goes Up May Come Down. Inflamm Bowel Dis. 2020;26(4):591–2.
Wang R, Li Z, Liu S. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: a systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023;13(3):186–92.
Burisch J, Jess T, Martinato M. The burden of inflammatory bowel disease in Europe. J Crohn’s Colitis. 2013;7(4):322–37.
Barreiro M, Molero A, Artime E, et al. Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review. Adv Ther. 2023;8(3)1975–2014.
Miyatani Y, Kobayashi T. Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease. Digestion. 2023;104(1):66–73.
Frias C, Colombel J, Torres J. De-escalation of Therapy in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2018;20(8):35–9.
Panaccione R. Mechanisms of Inflammatory Bowel Disease. Gastroenterol Hepatol. 2013;9(8):529–34.
Su H, Chiu Y, Chiu C. Inflammatory bowel disease and its treatment in 2018: Global and Taiwanese status updates. J Formos Med Assoc. 2019;118(7):1083–92.
McDowell C, Farooq U, Haseeb M. Inflammatory Bowel Disease. StatPearls. 2023.
Ballester M, Martí D, Tosca J. Disease severity and treatment requirements in familial inflammatory bowel disease. Int J Colorectal Dis. 2017;32(8):1197–205.
Brunet E, Roig C, Vela E. Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population-based analysis. Ann Med. 2018;50(7):613–9.
Chang J. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med. 2020;383(27):2652–64.
Sturm A, Maaser C, Calabrese E. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohn’s Colitis. 2019;13(3):273–84.
Trivedi P, Adams D. Chemokines and chemokine receptors as therapeutic targets in inflammatory bowel disease; Pitfalls and promise. J Crohn’s Colitis. 2018;12(2):641–52.
Flynn S, Eisenstein S. Inflammatory Bowel Disease Presentation and Diagnosis. Surg Clin North Am. 2019;99(6):1051–62.
Inflammatory Bowel Disease. World Gastroenterology Organisation. 2023.
Yamamoto J, Bosques F, Paula J, et al. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn’s and Colitis Organisation. Rev Gastroenterol México. 2017;82(1):46–84.
Lee J, Kim E, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. Clin Endosc. 2019;52(2):129–36.
Dai C, Jiang M, Sun M, et al. Fecal markers in the management of inflammatory bowel disease. Postgrad Med. 2018;130(7):597–606.
Feuerstein J, Papamichael K, Popejoy S. Targeted Physician Education and Standardizing Documentation Improves Documented Reporting with Inflammatory Bowel Disease Quality Measures in a Large Academic and Private Practice. Dig Dis Sci. 2018;63(1):36–45.
Nguyen V, Mays J, Lang M. Knowledge Gaps in the Management of Postoperative Crohn’s Disease: A US National Survey. Dig Dis Sci. 2018;63(1):53–60.
Mitrev N, Vande N, Seow C. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46(11):1037–53.
Maaser C, Sturm A, Vavricka S. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohn’s Colitis. 2019;13(2):144–64.
Gallo G, Kotze P, Spinelli A. Surgery in ulcerative colitis: When? How? Best Pract Res Clin Gastroenterol. 2018;32–33(8):71–8.
Pariente B, Hu S, Bettenworth D, et al. Treatments for Crohn’s Disease–Associated Bowel Damage: A Systematic Review. Clin Gastroenterol Hepatol. 2019;17(5):847–56.
Chahal J, Sriranganathan D, Poo S, et al. Network meta-analysis: efficacy and safety of treatments for fistulising Crohn’s disease. Eur J Gastroenterol Hepatol. 2023;35(7):702–10.
Barberio B, Gracie D, Black C, et al. Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn’s disease: systematic review and network meta-analysis. Gut. 2023;72(2):264–74.
Shehab M, Alrashed F, Heron V, et al. Comparative Efficacy of Biologic Therapies for Inducing Response and Remission in Fistulizing Crohn’s Disease: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Inflamm Bowel Dis. 2023;29(3):367–75.
Singh S, Murad M, Fumery M, et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002–14.
Cholapranee A, Hazlewood G, Kaplan G et al. Systematic review with meta-analysis: Comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn’s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther. 2019;45(10):1291–9.
Taxonera C, Olivares D, López O, et al. Meta-analysis: Real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610–9.
Qiu B, Liang J, Li C. Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2022;101(40):305–9.
Nielsen O, Steenholdt C, Juhl C, et al. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine. 2020;20(5):100271–9.
Santiago M, Dias C, Alves C, et al. The Magnitude of Crohn’s Disease Direct Costs in Health Care Systems (from Different Perspectives): A Systematic Review. Inflamm Bowel Dis. 2022;28(10):1527–36.
Trigo C, Gimeno V, López A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm. 2020;27(6):355–9.
AlRuthia Y, Almadi M, Aljebreen A, et al. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia. J Med Econ. 2020;23(10):1102–10.
Paschos P, Katsoula A, Salanti G, et al. Systematic review with network meta-analysis: the impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment Pharmacol Ther. 2018;48(11–12):1174–85.
Cichewicz A, Tencer T, Gupte K, et al. A Systematic Review of the Economic and Health-Related Quality of Life Impact of Advanced Therapies Used to Treat Moderate-to-Severe Ulcerative Colitis. Adv Ther. 2023;40(5):2116–9.
Solitano V, Facciorusso A, Jess T, et al. Comparative Risk of Serious Infections With Biologic Agents and Oral Small Molecules in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2023;21(4):907–21.
Singh S, Facciorusso A, Dulai P, et al. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020;18(1):69–81.
Shehab M, Alrashed F, Alkazemi A, et al. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol. 2023;17(5):469–77.
Chupin A, Perduca V, Meyer A, et al. Systematic review with meta-analysis: comparative risk of lymphoma with anti-tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;52(8):1289–97.
Wang L, Chen P, He S, et al. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review. World J Gastroenterol. 2023;29(29):4481–9.
Gisbert J, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. J Crohns Colitis. 2020;14(5):694–709.
Kucha P, Zagórowicz E, Walkiewicz D, et al. Biologic treatment of inflammatory bowel disease in Poland, 2012–2020: nationwide data. Polish Arch Intern Med. 2022;132(8):2012–20.
Jung Y, Han M, Park S, et al. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study. Dig Dis Sci. 2020;65(5):1436–44.
Vasudevan A, Gibson P, Langenberg D. Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(9):1462–73.
Fernández D, Dávila V. Frequency of use and cost of biologic treatment for inflammatory bowel disease and inflammatory bowel disease-associated arthropathy in Colombia in 2019. Rev Gastroenterol México. 2023;2(6):99–104.
Vass P, Démuth B, Hirsch E, et al. Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals. J Control Release. 2019;296(2):162–78.
Nieto J, Arajol C, Carmona L, et al. Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy. 2021;13(5):433–58.
Quaresma A, Coy C, Damião A, et al. Biological therapy penetration for inflammatory bowel disease in Latin America: Current status and future challenges. Arq Gastroenterol. 2019;56(3):318–22.
Dohos D, Hanák L, Szakács Z, et al. Systematic review with meta‐analysis: the effects of immunomodulator or biological withdrawal from mono‐ or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2021;53(2):220–33.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Evelyn Estefanía Jaramillo Castillo, Danilo Muñoz Palomeque
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores conservan los derechos morales y patrimoniales de sus obras. Puesto que Salud ConCiencia es una publicación de acceso abierto, los lectores pueden reproducir total o parcialmente su contenido siempre y cuando proporcionen adecuadamente el crédito a los autores correspondientes y a la revista misma.
Nuestra revista se rige por las políticas internacionales SHERPA/RoMEO: Revista verde: Permiten el autoarchivo tanto del pre-print (borrador de un trabajo) como del post-print (la versión corregida y revisada por pares) y hasta de la versión final (maquetada tal como saldrá publicada en la revista).
Véase también "Derechos de autor y licencias".
